EMA's PRAC recommends new restrictions on domperidone & diacerein
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that products containing domperidone should remain on the market but with additional restrictions to reduce the risk of serious cardiac side-effects. The committee has also advised restrictions on diacerein-containing drugs in order to manage the risks of severe diarrhea and liver disorders, reversing its earlier recommendation to suspend the drug.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.